The Effects of Cilnidipine on Metabolic Syndrome Improvement
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
Abnormalities of glucose, insulin and lipoprotein metabolism are common in patients with
hypertension, and these metabolic abnormalities are reported to be related to insulin
resistance. Therefore, whenever treating such patients, antihypertensive agents that may have
the added effect of improving insulin resistance should be selected. CinalongTM (Cilnidipine)
is expected to improve metabolic syndrome as well as insulin resistance by its dual effects
on L and N-type calcium (Ca) channels. In this study, the researchers investigate the effects
of CinalongTM on insulin resistance and other metabolic related factors.